Loading...
Otsuka Holdings Co., Ltd.
4578.T•JPX
HealthcareDrug Manufacturers - General
¥6778.00
¥-102.00(-1.48%)
Otsuka Holdings Co., Ltd. (4578.T) Financial Performance & Statements
Review Otsuka Holdings Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
15.42%
↑ 15.42%
Operating Income Growth
131.76%
↑ 131.76%
Net Income Growth
182.13%
↑ 182.13%
Operating Cash Flow Growth
25.21%
↑ 25.21%
Operating Margin
17.90%
↑ 17.90%
Gross Margin
72.20%
↑ 72.20%
Net Profit Margin
14.66%
↑ 14.66%
ROE
13.35%
↑ 13.35%
ROIC
14.32%
↑ 14.32%
Otsuka Holdings Co., Ltd. (4578.T) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Otsuka Holdings Co., Ltd. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $599.78B | $621.15B | $589.41B | $519.52B |
| Cost of Revenue | $177.69B | $166.53B | $164.41B | $151.80B |
| Gross Profit | $422.09B | $454.62B | $425.003B | $367.71B |
| Gross Profit Ratio | $0.70 | $0.73 | $0.72 | $0.71 |
| R&D Expenses | $91.25B | $76.20B | $71.56B | $72.39B |
| SG&A Expenses | $265.12B | $241.33B | $239.97B | $213.75B |
| Operating Expenses | $359.57B | $317.53B | $311.53B | $286.14B |
| Total Costs & Expenses | $537.27B | $484.06B | $475.94B | $437.94B |
| Interest Income | $0.00 | $0.00 | $10.49B | $10.09B |
| Interest Expense | $0.00 | $8.89B | $2.63B | $2.03B |
| Depreciation & Amortization | $27.56B | $27.02B | $27.34B | $26.06B |
| EBITDA | $90.62B | $138.48B | $154.36B | $110.82B |
| EBITDA Ratio | $0.15 | $0.22 | $0.26 | $0.21 |
| Operating Income | $62.52B | $137.09B | $113.47B | $81.58B |
| Operating Income Ratio | $0.10 | $0.22 | $0.19 | $0.16 |
| Other Income/Expenses (Net) | $17.32B | -$34.51B | $7.86B | $18.50B |
| Income Before Tax | $79.84B | $102.58B | $30.93B | $92.69B |
| Income Before Tax Ratio | $0.13 | $0.17 | $0.05 | $0.18 |
| Income Tax Expense | $72.45B | $29.46B | $10.39B | $21.18B |
| Net Income | $151.45B | $83.88B | $30.42B | $77.38B |
| Net Income Ratio | $0.25 | $0.14 | $0.05 | $0.15 |
| EPS | $281.40 | $154.71 | $56.04 | $142.59 |
| Diluted EPS | $281.40 | $154.71 | $56.04 | $142.59 |
| Weighted Avg Shares Outstanding | $538.20M | $542.14M | $542.80M | $542.65M |
| Weighted Avg Shares Outstanding (Diluted) | $538.20M | $542.14M | $542.80M | $542.65M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan